Blackstone Inc
ATXS

Blackstone Inc’s Astria Therapeutics ATXS Stock Holding History

Blackstone Inc’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-33,470
Closed -$1.29M – 172
2020
Q2 		$1.29M Hold
33,470
– – 0.01% 132
2020
Q1 		$833K Hold
33,470
– – 0.01% 71
2019
Q4 		$1.19M Hold
33,470
– – 0.01% 59
2019
Q3 		$1.08M Hold
33,470
– – 0.01% 61
2019
Q2 		$1.62M Hold
33,470
– – 0.01% 75
2019
Q1 		$1.59M Hold
33,470
– – 0.01% 65
2018
Q4 		$878K Buy
+33,470
New +$1.27M ﹤0.01% 47

Other funds holding ATXS

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Blackstone Inc's ATXS Position: Q3 2020 in Review

Blackstone Inc sold out of Astria Therapeutics (ATXS) in Q3 2020, closing a stake of 33,470 shares — an estimated $1.29M sold.

Blackstone Inc first reported a position in ATXS in Q4 2018 and held it in 7 quarters. The position peaked at $1.62M in Q2 2019. 51 funds tracked by Wall St. Rank hold ATXS as of Q3 2020.

  • Blackstone Inc reported no remaining Astria Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Blackstone Inc sold 33,470 Astria Therapeutics shares in Q3 2020, an estimated $1.29M.
  • Blackstone Inc first reported a position in Astria Therapeutics in Q4 2018 and held it in 7 quarters.
  • Blackstone Inc's Astria Therapeutics position peaked at $1.62M in Q2 2019.
  • 51 funds tracked by Wall St. Rank held Astria Therapeutics as of Q3 2020.

Based on Blackstone Inc's 13F filing for Q3 2020, filed 16 Nov 2020.